# OnCo record enasidenib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/enasidenib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "enasidenib" ;
  schema:name "Enasidenib"@en ;
  schema:description "Enasidenib is the IDH2 counterpart of ivosidenib, approved in the US for relapsed disease but never approved in Europe after it failed to extend survival in a confirmatory trial."@en ;
  schema:url <https://onco.cc/drugs/enasidenib/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Enasidenib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q27077182> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Enasidenib> ;
  onco:status "approved" ;
  onco:tag "confirmatory-trial-negative" ;
  onco:modality "Small-molecule IDH2 inhibitor" ;
  schema:alternateName "Idhifa" ;
  onco:approval "US 2017: Relapsed/refractory IDH2-mutated AML" ;
  onco:related <https://onco.cc/biomarkers/idh2-mutation/> ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/aml-idh/>, <https://onco.cc/cancers/sinonasal-undifferentiated-carcinoma/> ;
  onco:technologies <https://onco.cc/technologies/epigenetic-drugs/>, <https://onco.cc/technologies/idh-inhibitors/> ;
  onco:targets <https://onco.cc/targets/idh/> ;
  onco:companies <https://onco.cc/companies/bms/> ;
  onco:terms <https://onco.cc/terms/differentiation-syndrome/> .